#ipsen — Public Fediverse posts

https://www.europesays.com/ch/27264/ FDA pushes back decision on Sanofi’s BTK inhibitor; Roche makes a deal with Starpharma #Genentech #Ipsen #LiverFailure #MultipleSclerosis #NewsBriefing #Obesity #Roche #Sanofi #SciwindBiosciences #Starpharma #tolebrutinib

Who’s Out? ❌

#Merck, #Ipsen, #Sanofi and #GSK fall short overall.

Not good enough companies to be compelling for the next stage.

If you think any deserved a place, let me know!

(4/5)

Who’s Out? ❌

#Merck, #Ipsen, #Sanofi and #GSK fall short overall.

Not good enough companies to be compelling for the next stage.

If you think any deserved a place, let me know!

(4/5)

Company Snapshots 🔍

2024 PEG snapshot:
📈 #NovoNordisk – growth outpacing valuation → undervalued standout.
⚖️ #Novartis, #Merck, #AstraZeneca – solid growth, but P/Es are sky-high.
🚫 #Sanofi, #GSK, #Ipsen – negative earnings growth = PEG not meaningful.

PEG = P/E ÷ growth → simple in theory, tricky in practice!

(2/5)

Company Snapshots 🔍

2024 PEG snapshot:
📈 #NovoNordisk – growth outpacing valuation → undervalued standout.
⚖️ #Novartis, #Merck, #AstraZeneca – solid growth, but P/Es are sky-high.
🚫 #Sanofi, #GSK, #Ipsen – negative earnings growth = PEG not meaningful.

PEG = P/E ÷ growth → simple in theory, tricky in practice!

(2/5)

Company Snapshots 🔍

2024 PEG snapshot:
📈 #NovoNordisk – growth outpacing valuation → undervalued standout.
⚖️ #Novartis, #Merck, #AstraZeneca – solid growth, but P/Es are sky-high.
🚫 #Sanofi, #GSK, #Ipsen – negative earnings growth = PEG not meaningful.

PEG = P/E ÷ growth → simple in theory, tricky in practice!

(2/5)

Company Snapshots 🔍

2024 PEG snapshot:
📈 #NovoNordisk – growth outpacing valuation → undervalued standout.
⚖️ #Novartis, #Merck, #AstraZeneca – solid growth, but P/Es are sky-high.
🚫 #Sanofi, #GSK, #Ipsen – negative earnings growth = PEG not meaningful.

PEG = P/E ÷ growth → simple in theory, tricky in practice!

(2/5)

2020–2024 results:

The picture splits sharply:
🟢 #Novartis: strong margin gains, signaling real efficiency wins.
🟡 #NovoNordisk: rare balance of high growth and stable margins.
🔴 #Sanofi, #GSK, #Ipsen: margin erosion despite growth.
⚪ #AstraZeneca & #Merck: steady on both fronts.

(2/5)

2020–2024 results:

The picture splits sharply:
🟢 #Novartis: strong margin gains, signaling real efficiency wins.
🟡 #NovoNordisk: rare balance of high growth and stable margins.
🔴 #Sanofi, #GSK, #Ipsen: margin erosion despite growth.
⚪ #AstraZeneca & #Merck: steady on both fronts.

(2/5)

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC

Ipsen Pharma Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive famil…
#Japan #JP #JapanNews #bileacid #Ipsen #liverfailure #news #odevixibat #PFIC #ProgressiveFamilialIntrahepaticCholestasis #pruritussymptoms #regulatoryapproval #treatmentoption
https://www.alojapan.com/1373348/bylvay-odevixibat-approved-in-japan-for-rare-liver-disease-pfic/

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC

Ipsen Pharma Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive famil…
#Japan #JP #JapanNews #bileacid #Ipsen #liverfailure #news #odevixibat #PFIC #ProgressiveFamilialIntrahepaticCholestasis #pruritussymptoms #regulatoryapproval #treatmentoption
https://www.alojapan.com/1373348/bylvay-odevixibat-approved-in-japan-for-rare-liver-disease-pfic/

https://www.alojapan.com/1373348/bylvay-odevixibat-approved-in-japan-for-rare-liver-disease-pfic/ Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC #BileAcid #Ipsen #Japan #JapanNews #LiverFailure #news #odevixibat #PFIC #ProgressiveFamilialIntrahepaticCholestasis #PruritusSymptoms #RegulatoryApproval #TreatmentOption Ipsen Pharma Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offe

https://www.alojapan.com/1373348/bylvay-odevixibat-approved-in-japan-for-rare-liver-disease-pfic/ Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC #BileAcid #Ipsen #Japan #JapanNews #LiverFailure #news #odevixibat #PFIC #ProgressiveFamilialIntrahepaticCholestasis #PruritusSymptoms #RegulatoryApproval #TreatmentOption Ipsen Pharma Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offe

#Gleichheit, #Gleichheitssatz
Art. 3 Abs. 1 GG

#Kritik an #Hineinlesen von #Verhältnismäßigkeit in #Gleichheitssatz

#Neue #Formel
#Gleitformel

#Ipsen
-> #Methodisch nicht #kontrollierbare #Abwägungsdiffusion
-> #Übermaßverbot passt nicht auf #Beziehungsgefüge
#Hufen
-> #Gleichheitsgerechtigkeit so nicht #vorhersehbar
#Kischel
-> #Schaffung #weiterer #Gleichheitssätze über Art. 3 Abs. 3 hinaus

#Rechtssetzungsgleichheit; #Rechtsanwendungsgleichheit

#Vorlesung 21,3
#Grundrechte #Nußberger

#Gleichheit, #Gleichheitssatz
Art. 3 Abs. 1 GG

#Kritik an #Hineinlesen von #Verhältnismäßigkeit in #Gleichheitssatz

#Neue #Formel
#Gleitformel

#Ipsen
-> #Methodisch nicht #kontrollierbare #Abwägungsdiffusion
-> #Übermaßverbot passt nicht auf #Beziehungsgefüge
#Hufen
-> #Gleichheitsgerechtigkeit so nicht #vorhersehbar
#Kischel
-> #Schaffung #weiterer #Gleichheitssätze über Art. 3 Abs. 3 hinaus

#Rechtssetzungsgleichheit; #Rechtsanwendungsgleichheit

#Vorlesung 21,3
#Grundrechte #Nußberger